Outlook Therapeutics reports FY25 EPS ($1.79) vs ($4.06) last year

Reports FY25 revenue $1.413M. “Over the course of fiscal year 2025, our team has worked diligently to position Outlook Therapeutics (OTLK) for success. We are preparing now for potential approval and progressing commercial launch activities in the U.S., as we await a decision from the FDA in just a few short weeks,” commented Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “In Europe, our initial shipments of inventory are being used to prime and prepare to grow the market. Commercial activities remain ongoing as we push ahead with our efforts to expand into the next wave of country launches, including Austria and the Netherlands. Outside the U.S., we continue to identify potential partners for additional expansion. As we close out the remainder of 2025, our commitment remains focused on providing patients and physicians with access to an approved ophthalmic formulation of bevacizumab.”